

Investment Objective

The investment objective of the Kieger UCITS Fund - Kieger Impact Healthcare Fund is to achieve long term capital growth by principally investing in equities of healthcare and healthcare related companies or issuers worldwide (including Emerging Markets) with a focus on issuers that contribute to the realisation of the healthcare related United Nations Sustainable Development Goals. The fund is actively managed by the Investment Manager.

SFDR classification: Article 9

The fund has sustainable investment as its objective.

Key Information

General Information

ISIN	LU2488093530
BLOOMBERG	KGIHAAC LX
Fund Inception	01/10/2020
Share Class Inception	20/03/2023
Total Assets	CHF 77.5m
Fund Currency	CHF
Domicile	Luxembourg
Regulatory Status	SICAV
Legal Structure	UCITS
Dealing Frequency	Daily (CET 12pm)
Settlement	T+2
Distribution Policy	Accumulating

Service Providers

Management Company	FundRock Management Co. SA
Investment Manager	Kieger AG
Custodian Bank/ Administrator	Northern Trust Global Services SE
Auditor	Ernst & Young SA

Fund Management

Urban Fritsche (Lead Mgr)
Maria Specogna (Co-Mgr)
Raphael Oesch (Co-Mgr)

Portfolio Statistics (3-Year Annualised)

	Fund
Volatility	14.67%
Sharpe Ratio	-1.02
Tracking Error	13.65%
Information Ratio	-1.09
Beta	1.16
Active Share	94.00%

Largest Holdings (%)

Ionis Pharmaceuticals Inc	3.5%
Organon & Co	3.2%
Sandoz Group AG	3.1%
Radnet Inc	3.1%
Natera Inc	3.1%
Exact Sciences Corp	3.1%
Ambu A/S	3.1%
Abbott Laboratories	3.0%
Revvity Inc	3.0%
Agilon Health Inc	3.0%
Total Top 10 - out of 49	31.2%


Performance (%)

Performance data are net of management fees, but do not reflect sales charges or the effect of taxes.



Past performance is no indication of current or future performance.

	1 Month	3 Months	YTD	1 Yr	3 Yrs	5 Yrs
CHF B Class Accumulating	-4.71%	-7.37%	-0.92%	-10.65%	-	-




Market review: The end of spring was the scene for unsteady markets, with large moves across sectors. In the healthcare space, markets were moved by the news releases from many scientific conferences. At ASCO, antibody-drug conjugates and combo therapies stole the show, with options and better treatment constantly improving for patients. The EASL (hepatology) EULAR (rheumatology), and ADA (diabetes) conferences have shown that groundbreaking research is also happening outside of oncology. In particular, early but highly promising data for application cell therapies in diabetes and lupus treatment were presented at these conferences. The month also featured various investor conferences, giving markets an insight of the direction of travel for the second half of the year. The FDA was also active during the month, with multiple approvals and advisory committees held. Among other decisions, an FDA advisory committee voted against an MDMA (psychedelic drug) treatment which had been investigated to treat post traumatic stress disorder (PTSD). While the advisory panel clearly expressed the potential benefit of psychedelic therapies, it also emphasized that well run clinical trials will be needed for approval and its comments will help inform decisions around future clinical development strategies. Overall, we continue to see all systems go for the healthcare sector, driven by sustained demand and innovation.

Portfolio changes: No new position was initiated and no position was exited.


Performance review: The largest contributors were Ionis (+73 bps / Positive read-across from Alnylam. Later in June, it was announced that the FDA has accepted for Priority Review the New Drug Application for olezarsen for the treatment of adults with familial chylomicronemia syndrome), Guardant (+22 bps / two positive broker upgrades in June) and Aspen (+16 bps / No specific news). The largest detractors were Teladoc (-67 bps / No specific news, continued negative sentiment from February), BioNTech (-65 bps): the FDA has placed a partial clinical hold (affecting new patient enrollment in the US) on a phase 1 clinical trial) and Inspire (-35 bps / Eli Lilly has now published the full results of the SURMOUNT-OSA study, following the release of top-line results in April. The data revealed that 42.2% of patients in the non-PAP group and 50.2% in the PAP group achieved disease resolution, surpassing investor expectations. Although this could potentially reduce the number of patients opting for surgical procedures in favor of the drug over time, we believe this will not impact sales. The total addressable market remains largely untapped, with penetration still in the single digits).

ESG: Firms in the portfolio did not report any material ESG issues in June.


Regional Exposure (%)



Sector Exposure (%)




Market Cap Breakdown (%)



Large = >15bn, Mid = 5-15bn, Small = <5bn

Impact Theme Allocation (%)



Share Class Information

Share Class	ISIN	Bloomberg	Investment Management Fee	TER - as of Dec 2023	Minimum Investment	NAV
USD A Class Accumulating	LU2207278073	KGIHAUA LX	1.00%	1.21%	500,000	80.96
CHF A (H) Class Acc	LU2207278404	KGIHAHC LX	1.00%	1.27%	500,000	84.62
USD B Class Accumulating	LU2488093613	KGIHAUU LX	1.00%	1.22%	5,000	92.57
EUR B Class Accumulating	LU2488093456	KGIHAAE LX	1.00%	1.22%	5,000	92.27
CHF B Class Accumulating	LU2488093530	KGIHAAC LX	1.00%	1.22%	5,000	90.51
USD R Class Accumulating	LU2207278669	KGIHRUA LX	2.00%	2.22%	2,000	90.08

Disclaimer

This is a marketing communication. The information contained therein is intended only for information purposes and does not represent an offer to purchase or sell financial instruments. The source of the information is considered reliable; however, the accuracy or completeness of such information is not guaranteed. The information is subject to change from time to time without notice. This information neither represents any investment / legal / tax advice, or any recommendation. The Agent (as defined below) points out that every investment decision should be made after consulting an advisor.

The information in this document is intended exclusively for professional clients within the meaning of Annex II MiFID II. Past performance is no indication of current or future performance. The performance data do not take account of the commissions and costs incurred on the issue and redemption of units. Please refer to and read carefully the Prospectus of Kieger UCITS Fund (the "Fund") and the Key Investor Information Document ("KIID") of the Kieger UCITS Fund - Kieger Impact Healthcare Fund in their latest versions before making any final investment decisions. These documents can be obtained in English from the website <https://kieger.com/ucits> or any agents as further described below.

A decision to invest in the sub-fund should take into account all the characteristics or objectives of the sub-fund as disclosed in the Prospectus.

A summary of the investor rights is available in English at

<https://kieger.com/regulatory-disclosures> Further information about the sustainability-related aspects of the Fund is available at

<https://kieger.com/regulatory-disclosures>. The fund is marketing in multiple member states of European Union and Switzerland. The management company reserves the right to terminate the arrangements made for the marketing of the Fund in accordance with Article 93a of the Directive 2009/65/EC.

Information for Swiss Investors:

This is an advertising document. The state of the origin of the fund is Luxembourg. In Switzerland, the representative is Acolin Fund Services AG, Leutschenbachstrasse 50, CH-8050 Zurich, whilst the paying agent is Banque Cantonale de Genève, 17, Quai de l'Île, CH-1204 Geneva. The prospectus, the key information documents or the key investor information documents, the articles of association as well as the annual and semi-annual reports may be obtained free of charge from the representative.

Information for German Investors:

The Fund's Facilities agent in Germany is Acolin Europe AG, with the registered office at Rechneraustraße 11a-c, 78467 Konstanz. The Prospectus (in English) and the KIID (in German), may be obtained free of charge at the registered office of the Facilities agent, or electronically by Email facilityagent@acolin.com, or by using the contact form at <https://acolin.com/services/facilities-agency-services>.

Information for Austrian Investors: The Facility agent according to EU Directive 2019/1160 Article 92, as well as tax representative in Austria, is Erste bank der oesterreichischen Sparkassen AG, with the registered office at Am Belvedere 1, A-1100 Vienna. The Prospectus (in English) and the KIIDs (in German) may be obtained free of charge at the registered office of the Facility agent, or electronically by Email foreignfunds0540@erstebank.at

Marketing in the European Union:

The issuer of this marketing communication in Europe (excluding Switzerland) is Kieger Capital Partners S.à.r.l. Kieger Capital Partners S.à.r.l. ("Tied Agent") is a tied agent within the meaning of Article 29 (3) of Directive 2014/65/EU ("MiFID II" as implemented in the respective national legislation) of Acolin Europe AG, which is authorised and regulated by the German Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). The Tied Agent is entered in the public register of tied agents held by CSSF in his home country Luxembourg. Within the scope of providing financial services ("investment brokerage" within the meaning of Annex I A (1) MiFID II as implemented in the respective national legislation by promotion of the potential investor's willingness to enter into a transaction but excluding the reception and transmission of orders in relation to one or more financial instruments), the Tied Agent acts exclusively on behalf and for the account of Acolin Europe AG and undertakes to exclusively distribute the Kieger UCITS funds.

The information provided by the Tied Agent is intended for informational purposes only and does not represent an offer to purchase or sell financial instruments. All information is provided without any guarantee. This information neither represents any investment / legal / tax advice, nor any recommendation. The Agent points out that every investment decision should be made after consulting an advisor. The information is intended exclusively for professional clients within the meaning of Annex II MiFID II.

The information provided may not be copied or further distributed to third parties without the prior consent of Acolin Europe AG. The information may not be given to persons or companies that do not have their ordinary residence or domicile in the countries in which Acolin Europe AG is authorized to provide financial services. In particular, the information may not be made available to US citizens or persons residing in the USA. This document may not be copied or used for other purposes, nor may the content of the document be forwarded to third parties.